Skip to main content
main-content

Type 2 diabetes

Highlights

01-29-2019 | Cardiovascular outcomes | Highlight | News

Gap in cardiovascular risk not closing for people with type 2 diabetes

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

01-17-2019 | Glucokinase activators | Highlight | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-19-2018 | Insulin degludec | Highlight | News

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

12-14-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

11-21-2018 | Risk factors | Highlight | News

Shift work plus unhealthy lifestyle add up to high diabetes risk

The total diabetes risk associated with the combination of rotating shift work and an unhealthy lifestyle is greater than that of the two added together, shows an analysis of the Nurses’ Health Studies.

11-20-2018 | Insulin | Highlight | News

Research predicts ‘highly inadequate’ insulin access in coming years

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

10-30-2018 | Glycemic control | Highlight | News

Improved oral health could help glycemic control in type 2 diabetes

A year of intensive periodontal treatment is associated with a significant reduction in glycated hemoglobin levels in patients with type 2 diabetes and moderate-to-severe periodontitis, UK researchers report.

10-16-2018 | Metabolic surgery | medwireNews | News

Marked reduction in vascular events in diabetes patients after bariatric surgery

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

10-10-2018 | Laparascopic gastric band | EASD 2018 | News

Gastric banding has little effect on beta-cell decline in early type 2 diabetes

The results of the adult surgery study from the RISE consortium show that gastric banding has only a small effect on the deterioration of beta-cell function relative to metformin, despite causing markedly greater weight loss.

10-09-2018 | Diabetes prevention | EASD 2018 | News

Mixed results from the diabetes prevention PREVIEW project

The PREVIEW project investigators have reported broadly positive results, but tempered by issues such as a high dropout rate.

10-05-2018 | Hyperglycemia | EASD 2018 | News

ADA/EASD consensus report on managing hyperglycemia in type 2 diabetes published

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

10-04-2018 | GLP-1 agonists | EASD 2018 | News

Promising phase II data for dual GIP and GLP-1 receptor agonist

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

10-03-2018 | Lixisenatide | EASD 2018 | News

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

image credits